site stats

Phesgo product monograph

WebPHESGO Monographs Pertuzumab; trastuzumab; hyaluronidase-zzxf is a combination product for subcutaneous use. Both pertuzumab and trastuzumab are monoclonal … WebFood and Drug Administration

pdf.hres.ca

WebNote: Phesgo injection for subcutaneous use has different dosage and administration instructions than intravenous pertuzumab and trastuzumab products. Phesgo is supplied as: 1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase/15mL (80 mg, 40 mg, and 2,000 units/mL) of solution in a single-dose vial. WebDrug Monograph. Black Box Warnings; Adult Dosing; Peds Dosing; Contraindications/Cautions; Drug Interactions; Adverse Reactions; Safety/Monitoring ; … toyota dealer lees summit mo https://unicornfeathers.com

PHESGO CLINICAL PHARMACOLOGY DRUG MONOGRAPH - WellRx

WebPrice Drugs PHESGO QTY 15 • 1200-600MG • VIAL • Near 77381 Add to Medicine Chest Set Price Alert PERTUZUMAB (per TOOZ ue mab); TRASTUZUMAB (tras TOO zoo mab); … WebMar 1, 2024 · PHESGO is made up of two medicines combined together that belong to a group of medicines called monoclonal antibodies (pertuzumab and trastuzumab). • … WebPhesgo is a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. ... This medicinal product is subject to additional ... toyota dealer lewistown pa

PHESGO PEDIATRIC DRUG MONOGRAPH - wellrx.com

Category:PHESGO PEDIATRIC DRUG MONOGRAPH - wellrx.com

Tags:Phesgo product monograph

Phesgo product monograph

DailyMed - PHESGO- pertuzumab, trastuzumab, and hyaluronidase …

WebPhesgo is indicated for use in combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received … WebThe NDC code 50242-260 is assigned by the FDA to the product Phesgo which is a human prescription drug product labeled by Genentech, Inc.. The generic name of Phesgo is pertuzumab, trastuzumab, and hyaluronidase-zzxf. ... If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be ...

Phesgo product monograph

Did you know?

WebThis product contains 3 ingredients: pertuzumab, trastuzumab, and hyaluronidase. It is used to treat a certain type of breast cancer. The cancer cells make more than the usual amount of a certain... WebPhesgo combines pertuzumab and trastuzumab into a single dose. It is given by a needle just under the skin (subcutaneously) instead of through a needle in a vein (intravenously). This means that treatment can be given more quickly …

WebAug 8, 2024 · Phesgo contains a combination of hyaluronidase, pertuzumab, and trastuzumabis. Phesgo is a cancer medicine that is used alone or with other medicines to treat early-stage breast cancer. Phesgo is also used to treat HER2-positive breast cancer that is advanced or has spread to other parts of the body (metastatic). WebMar 19, 2008 · Perjeta, Perjeta-Herceptin, Phesgo Generic Name Pertuzumab DrugBank Accession Number DB06366 Background Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2).

Web• PHESGO has different dosage and administration instructions than intravenous pertuzumab and trastuzumab products. • Do not administer intravenously. (2.2) • Perform … WebPediatric drug monographs for PHESGO provide an overview of the drug product, therapeutic uses, key development issues, regulatory information, and therapeutic classifications on ScriptSave WellRx.

WebInjection time. The first dose of PHESGO takes about 8 minutes to inject. Other doses take about 5 minutes to inject. Your healthcare team will wait at least 30 minutes after the first dose, and at least 15 minutes after each following dose, to check for any reactions. If side effects occur, your healthcare provider may slow, delay, or stop ...

Webpdf.hres.ca toyota dealer lincoln park chicagoWebMar 18, 2024 · Phesgo contains pertuzumab and trastuzumab which provides the therapeutic effect of this medicinal product and vorhyaluronidase alfa, an enzyme used to … toyota dealer logan wvWebMar 16, 2024 · The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. Last updated on emc: 16 Mar 2024. This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. View or print the patient leaflet as PDF. toyota dealer locator by zip codeWebDec 18, 2024 · You may label your product with the proprietary name, Phesgo, and market it in 1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase per 15 mL injection in a single-dose vial and 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase per 10 mL injection in a single-dose toyota dealer lexington kyWebPhesgo® contains two separate monoclonal antibodies, trastuzumab and pertuzumab. Previously, trastuzumab and pertuzumab were used separately or in combination to … toyota dealer little rockWebApr 9, 2024 · Product name: PHESGO Description: SINGLE USE VIAL Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and … toyota dealer loisdale road springfield vaWebPhesgo has different dosage and administration instructions than IV pertuzumab, IV trastuzumab, and SC trastuzumab when administered alone ... these are "non-preferred" brand drugs or specialty prescription products. 5: This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty ... toyota dealer long island